These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 12680225

  • 1. Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo.
    Vegesna V, O'Kelly J, Said J, Uskokovic M, Binderup L, Koeffle HP.
    Anticancer Res; 2003; 23(1A):283-9. PubMed ID: 12680225
    [Abstract] [Full Text] [Related]

  • 2. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M, Koshizuka K, Kawabata H, Yang R, Taub HE, Said J, Uskokovic M, Tsuruoka N, Koeffler HP.
    Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
    [Abstract] [Full Text] [Related]

  • 3. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
    Kubota T, Koshizuka K, Koike M, Uskokovic M, Miyoshi I, Koeffler HP.
    Cancer Res; 1998 Aug 01; 58(15):3370-5. PubMed ID: 9699668
    [Abstract] [Full Text] [Related]

  • 4. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
    Hisatake J, Kubota T, Hisatake Y, Uskokovic M, Tomoyasu S, Koeffler HP.
    Cancer Res; 1999 Aug 15; 59(16):4023-9. PubMed ID: 10463602
    [Abstract] [Full Text] [Related]

  • 5. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects.
    Campbell MJ, Reddy GS, Koeffler HP.
    J Cell Biochem; 1997 Sep 01; 66(3):413-25. PubMed ID: 9257197
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
    Skowronski RJ, Peehl DM, Feldman D.
    Endocrinology; 1995 Jan 01; 136(1):20-6. PubMed ID: 7530193
    [Abstract] [Full Text] [Related]

  • 9. 24-Oxo metabolites of vitamin D3 analogues: disassociation of their prominent antileukemic effects from their lack of calcium modulation.
    Shiohara M, Uskokovic M, Hisatake J, Hisatake Y, Koike K, Komiyama A, Koeffler HP.
    Cancer Res; 2001 Apr 15; 61(8):3361-8. PubMed ID: 11309293
    [Abstract] [Full Text] [Related]

  • 10. Growth inhibitory effects on human colon adenocarcinoma-derived Caco-2 cells and calcemic potential of 1 alpha,25-dihydroxyvitamin D3 analogs: structure-function relationships.
    Bischof MG, Redlich K, Schiller C, Chirayath MV, Uskokovic M, Peterlik M, Cross HS.
    J Pharmacol Exp Ther; 1995 Dec 15; 275(3):1254-60. PubMed ID: 8531089
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
    Barreto AM, Schwartz GG, Woodruff R, Cramer SD.
    Cancer Epidemiol Biomarkers Prev; 2000 Mar 15; 9(3):265-70. PubMed ID: 10750664
    [Abstract] [Full Text] [Related]

  • 13. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089.
    Zhang X, Jiang F, Li P, Li C, Ma Q, Nicosia SV, Bai W.
    Clin Cancer Res; 2005 Jan 01; 11(1):323-8. PubMed ID: 15671562
    [Abstract] [Full Text] [Related]

  • 14. Antileukemic effect of a synthetic vitamin D3 analog, HY-11, with low potential to cause hypercalcemia.
    Yoon JS, Kim JY, Park HK, Kim ES, Ahn KS, Yoon SS, Cho CG, Kim BK, Lee YY.
    Int J Oncol; 2008 Feb 01; 32(2):387-96. PubMed ID: 18202761
    [Abstract] [Full Text] [Related]

  • 15. Growth inhibitory effects of 1,25-dihydroxyvitamin D3 and its synthetic analogue, 1alpha,25-dihydroxy-16-ene-23yne-26,27-hexafluoro-19-nor-cholecalcifero l (Ro 25-6760), on a human colon cancer xenograft.
    Evans SR, Schwartz AM, Shchepotin EI, Uskokovic M, Shchepotin IB.
    Clin Cancer Res; 1998 Nov 01; 4(11):2869-76. PubMed ID: 9829754
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089.
    Perez-Stable CM, Schwartz GG, Farinas A, Finegold M, Binderup L, Howard GA, Roos BA.
    Cancer Epidemiol Biomarkers Prev; 2002 Jun 01; 11(6):555-63. PubMed ID: 12050097
    [Abstract] [Full Text] [Related]

  • 19. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth.
    Gavrilov V, Steiner M, Shany S.
    Anticancer Res; 2005 Jun 01; 25(5):3425-9. PubMed ID: 16101159
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.